Spyre Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 29, 2024
| SPYRE THERAPEUTICS, INC. | |
| By: | /s/ Scott Burrows |
| Scott Burrows | |
| Chief Financial Officer | |
| (Principal Financial Officer and Principal Accounting Officer) |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dr. Cameron Turtle and Mr. Scott Burrows, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Report on Form 10-K and to file same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Cameron Turtle, D.Phil | President and Chief Executive Officer and Director | February 29, 2024 |
| Cameron Turtle, D.Phil | (Principal Executive Officer) | |
| /s/ Scott Burrows | Chief Financial Officer | February 29, 2024 |
| Scott Burrows | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Russell J. Cox | Chairman of the Board | February 29, 2024 |
| Russell J. Cox | ||
| /s/ Jeffrey W. Albers | Director | February 29, 2024 |
| Jeffrey W. Albers | ||
| /s/ Peter Harwin | Director | February 29, 2024 |
| Peter Harwin | ||
| /s/ Michael Henderson, M.D. | Director | February 29, 2024 |
| Michael Henderson, M.D. | ||
| /s/ Tomas Kiselak | Director | February 29, 2024 |
| Tomas Kiselak | ||
| /s/ Mark McKenna | Director | February 29, 2024 |
| Mark McKenna | ||
| /s/ Laurie Stelzer | Director | February 29, 2024 |
| Laurie Stelzer | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.